Literature DB >> 29777722

Ca2+ signaling and spinocerebellar ataxia.

Chihiro Hisatsune1, Kozo Hamada2, Katsuhiko Mikoshiba3.   

Abstract

Spinocerebellar ataxia (SCA) is a neural disorder, which is caused by degenerative changes in the cerebellum. SCA is primarily characterized by gait ataxia, and additional clinical features include nystagmus, dysarthria, tremors and cerebellar atrophy. Forty-four hereditary SCAs have been identified to date, along with >35 SCA-associated genes. Despite the great diversity and distinct functionalities of the SCA-related genes, accumulating evidence supports the occurrence of a common pathophysiological event among several hereditary SCAs. Altered calcium (Ca2+) homeostasis in the Purkinje cells (PCs) of the cerebellum has been proposed as a possible pathological SCA trigger. In support of this, signaling events that are initiated from or lead to aberrant Ca2+ release from the type 1 inositol 1,4,5-trisphosphate receptor (IP3R1), which is highly expressed in cerebellar PCs, seem to be closely associated with the pathogenesis of several SCA types. In this review, we summarize the current research on pathological hereditary SCA events, which involve altered Ca2+ homeostasis in PCs, through IP3R1 signaling.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Calcium; Cerebellum; Endoplasmic reticulum; IP(3) receptor

Mesh:

Substances:

Year:  2018        PMID: 29777722     DOI: 10.1016/j.bbamcr.2018.05.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  9 in total

1.  Gene expression analysis of the cerebellar cortex in essential tremor.

Authors:  Regina T Martuscello; Chloë A Kerridge; Debotri Chatterjee; Whitney G Hartstone; Sheng-Han Kuo; Peter A Sims; Elan D Louis; Phyllis L Faust
Journal:  Neurosci Lett       Date:  2019-11-07       Impact factor: 3.046

Review 2.  Current and emerging treatment modalities for spinocerebellar ataxias.

Authors:  Shaila D Ghanekar; Sheng-Han Kuo; Joseph S Staffetti; Theresa A Zesiewicz
Journal:  Expert Rev Neurother       Date:  2022-02-10       Impact factor: 4.287

Review 3.  Type 3 inositol 1,4,5-trisphosphate receptor: A calcium channel for all seasons.

Authors:  Anjali Mangla; Mateus T Guerra; Michael H Nathanson
Journal:  Cell Calcium       Date:  2019-11-25       Impact factor: 6.817

4.  Aberrant IP3 receptor activities revealed by comprehensive analysis of pathological mutations causing spinocerebellar ataxia 29.

Authors:  Hideaki Ando; Matsumi Hirose; Katsuhiko Mikoshiba
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-14       Impact factor: 12.779

5.  Ataxic Symptoms in Huntington's Disease Transgenic Mouse Model Are Alleviated by Chlorzoxazone.

Authors:  Polina A Egorova; Aleksandra V Gavrilova; Ilya B Bezprozvanny
Journal:  Front Neurosci       Date:  2020-04-03       Impact factor: 4.677

6.  The Eighth ECS Workshop on "Calcium Signaling in Aging and Neurodegenerative Diseases".

Authors:  Jan B Parys; Cláudia F Pereira; Carlos Villalobos
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

7.  STIM2 Mediates Excessive Store-Operated Calcium Entry in Patient-Specific iPSC-Derived Neurons Modeling a Juvenile Form of Huntington's Disease.

Authors:  Vladimir A Vigont; Dmitriy A Grekhnev; Olga S Lebedeva; Konstantin O Gusev; Egor A Volovikov; Anton Yu Skopin; Alexandra N Bogomazova; Lilia D Shuvalova; Olga A Zubkova; Ekaterina A Khomyakova; Lyubov N Glushankova; Sergey A Klyushnikov; Sergey N Illarioshkin; Maria A Lagarkova; Elena V Kaznacheyeva
Journal:  Front Cell Dev Biol       Date:  2021-02-02

Review 8.  The Emerging Key Role of the mGluR1-PKCγ Signaling Pathway in the Pathogenesis of Spinocerebellar Ataxias: A Neurodevelopmental Viewpoint.

Authors:  Qin-Wei Wu; Josef P Kapfhammer
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

Review 9.  Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling.

Authors:  Dmitriy A Grekhnev; Elena V Kaznacheyeva; Vladimir A Vigont
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.